N1 Life is a biotech company that originated as a Stanford University spinout start-up to develop innovative tissue-focused drug delivery technologies for new therapeutics to address unmet medical needs. N1 Life was cofounded by Stanford professor Dr. Paul A. Wender,a world-renowned translational scientist, and Dr. Janice (Xiaoyu) Zang,an entrepreneurial scientist and rising star in the drug delivery field. The company operates with relentless courage based on proven success.
We apply our scientific-driven innovation combined with efficient project management to accelerate our path to success. Our success is built on the synergistic convergence of our intelligent scientists, committed advisors, global partners, and alliances with shared goals of improving translational success and solving unmet medical needs.
"Science advances human. Technology changes life."
N1 Team carries the mission of bridging the gap between research and clinic, and from bench to bed. N1 Life excels in translating innovative technologies with clinical potentials to clinical products.
At N1 Life, we apply a scientifically driven, unrestricted imagination, combined with proven efficient project management to accelerate our path to success. Our success is built on the synergistic convergence of our internal intelligent scientists, committed scientific advisors, global partners, and alliances. Together, we work towards achieving shared goals of improving translational success and solving unmet medical needs where tissue is the issue. By harnessing the power of multiple streams and teams, we aim to create greater global momentum toward disease eradication and improving lives.
We are a respected global company with laboratories and teams located in the United States, China, and other countries.
N1 Life bridges the gap between industry and academia. As a technology-centered company with 100% innovation-drive team, we embrace, utilize and adapt cutting-edge technologies for the goal of addressing unmet medical needs
From day one, N1 Life maintains a sustainable development and partnership model to save money, time, resources, and energy throughout the development of clinical products
Thanks to N1 technologies, we significantly cut down the cost of all N1 product development, which would make these novel treatments more accessible and affordable to all human beings and animals